Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer.

By R. Lord, J. Brabender, D. Gandara, V. Alberola, C. Camps, M. Dómine, F. Cardenal, J. Sánchez, P. Gumerlock, M. Taron and 4 more. Clinical Cancer Research, 2002

683 citations recorded by the source corpus.

View Paper: https://www.semanticscholar.org/paper/206a94123af7a73cb052255637b85a2d428c5489

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. G. Masters
2. David H. Johnson
3. S. Temin
4. William Pao
5. C. Azzoli
6. Sherman Baker
7. Hassan Lemjabbar-Alaoui
8. D. Longley

Citations in the corpus

• Lung cancer: Biology and treatment options. (2015, background): “Nearly 50% of NSCLC patients have low levels of ERCC1, and therefore could benefit from alternative therapies exploiting this tumor ERCC1 deficiency [19].”
• Apoptosis and Molecular Targeting Therapy in Cancer (2014, background): “Clinically, high levels of ERCC1 are correlated with poor response to platinum-based chemotherapy in ovarian, gastric, and nonsmall cell lung cancers (NSCLC) [184–186].”
• American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. (2009, result): “Two analyses found that low ERCC1 was a significant predictor of improved survival with cisplatinbased doublets.(164,165) Two others found nonsignificant trends of survival benefit from cisplatin-based doublets for patients with tumors with low ERCC1 compared with for patients with tumors with high ”
• Molecular mechanisms of drug resistance (2005, background): “Clinically, high levels of ERCC1 have been reported to correlate with poor response to platinum-based chemotherapy in ovarian, gastric, and non-small cell lung cancers (NSCLC) [71–73].”